Drug Costs SKYROCKETING? A new report exposes how powerful companies are squeezing out competition and inflating prices. The FTC exposes these "Middlemen" as part of the blame! Here’s Why! https://lnkd.in/e7saCBpJ
The Center for Biosimilars
Book and Periodical Publishing
Cranbury, NJ 16,026 followers
The authoritative resource for emerging therapies.
About us
Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.
- Website
-
http://www.centerforbiosimilars.com
External link for The Center for Biosimilars
- Industry
- Book and Periodical Publishing
- Company size
- 2-10 employees
- Headquarters
- Cranbury, NJ
- Type
- Privately Held
- Founded
- 2016
- Specialties
- biosimilars, biosimilar news, pharmaceuticals, policy, regulatory, and clinical
Locations
-
Primary
-
Cranbury, NJ 08512, US
Employees at The Center for Biosimilars
Updates
-
Biosimilars on the move! EU greenlights a new one, Genentech's eye drug is back, and there's hot switching data on a big-name biosimilar. Get all the deets here: https://lnkd.in/eYcFQmAi
-
-
A new study using a smartphone app found the biosimilar trastuzumab-dkst (Ogivri) to be just as safe and effective as Herceptin for HER2-positive breast cancer! Read more to see the data and learn about this innovative approach. https://lnkd.in/eHR5Yzf2
-
-
Biosimilars news is heating up! This week's top stories: interchangeability updates, new approvals, and overcoming barriers to biosimilars in oncology. Click the link below to watch the video of the top 5 articles of the week to learn more about these and other biosimilar advancements! https://lnkd.in/eFKnXkwQ
-
-
Brazil 🇧🇷 scores big! A study found Trastuzumab-dkst to be as effective and safe as the gold standard treatment. This is a major win for patients with HER2-positive breast cancer. Want to learn more about this game-changing therapy? https://lnkd.in/eCrkee3B
-
-
Biosimilars might be the life raft you need! 🆘 Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, breaks down innovative treatments that can deliver high-quality cancer care WITHOUT breaking the bank. She discusses: *US biologics market growing 12.5% annually over the past 5 years *Biologics projected to be 55% of the top 100 medications used in the US by 2026! *Areas she focuses on to promote biosimilars in her practice *Adoption of clinical management programs *PBM contract negotiations To read the full article: https://lnkd.in/ePiXXK-q
-
-
Samsung Bioepis' ustekinumab biosimilar (SB17) shows promise in a new study! This means it may offer a safe and effective alternative to the current treatment. The study found SB17 to be comparable to the existing medication in terms of: * PK bioequivalence * Safety * Tolerability * Immunogenicity Want to learn more? Check out the full article here: https://lnkd.in/ezYEzv-4
-
-
Eye on Pharma: Celltrion's Tocilizumab biosimilar shows promise in Phase 3 data! This could mean increased access to this treatment for rheumatoid arthritis patients. Plus, in other biosimilar news: Formycon starts clinical development of their Pembrolizumab biosimilar. Stay ahead of the curve with the latest updates on biosimilars! https://lnkd.in/eSZMjdNu
-
-
Top 3 Game-Changing Biosimilars You NEED to Know About! Wondering what's next in the biosimilar world? We sat down with Jeffrey Casberg, SVP of Pharmacy at IDP Analytics, who reveals the top 3 promising specialty drugs coming down the pipeline!** They're tackling HUGE areas like Alzheimer's, Fatty Liver Disease, and Pulmonary Hypertension!** 🫀 🫁 But there's a twist! The FDA is taking a closer look at one of them. What could it mean? Click the link to watch and hear all about: https://lnkd.in/e5Bi2n_j
-
-
Confused about rising drug costs? Watch a segment of our interview with Jeffrey Casberg, SVP of Pharmacy at IDP Analytics, to get the inside scoop on what's driving these high prices! Want to know what the future holds for drug affordability? Click the link to watch the interview 🎥 https://lnkd.in/euBQWQud
-